Treatment.com AI Announces Momentum Following Acquisition of Rocket Doctor, Highlighting Growth, Innovation, and National Recognition
Treatment.com AI (OTC: TREIF) reports significant progress following its acquisition of Rocket Doctor, showcasing strong growth metrics and strategic achievements. Rocket Doctor's patient volume surged 112% year-over-year in Alberta, serving over 36,000 patients in 2024, while physician adoption grew by 218% from 22 to 70 active physicians.
Key developments include partnerships with Central California Alliance for Health (450,000-member managed care plan) and Melanoma Canada, plus the deployment of their Medical Education Suite at the University of Minnesota Medical School, potentially reducing exam costs by 40%. The company received recognition as Top Clinical Innovator by the American Telemedicine Association and secured positions in prestigious programs including UC Berkeley Health Engine Accelerator and AARP AgeTech Accelerator.
Treatment.com AI (OTC: TREIF) annuncia importanti progressi dopo l'acquisizione di Rocket Doctor, evidenziando forti indicatori di crescita e risultati strategici. Il volume di pazienti di Rocket Doctor 猫 aumentato del 112% su base annua in Alberta, con oltre 36.000 pazienti serviti nel 2024, mentre l'adozione da parte dei medici 猫 cresciuta del 218%, passando da 22 a 70 medici attivi.
Tra le principali novit脿 si segnalano partnership con la Central California Alliance for Health (piano di assistenza gestita con 450.000 membri) e Melanoma Canada, oltre al lancio della loro Medical Education Suite presso la Facolt脿 di Medicina dell'Universit脿 del Minnesota, con un potenziale risparmio sui costi degli esami del 40%. L'azienda 猫 stata riconosciuta come Top Clinical Innovator dall'American Telemedicine Association e ha ottenuto posizioni in programmi prestigiosi come UC Berkeley Health Engine Accelerator e AARP AgeTech Accelerator.
Treatment.com AI (OTC: TREIF) informa de avances significativos tras la adquisici贸n de Rocket Doctor, mostrando s贸lidos indicadores de crecimiento y logros estrat茅gicos. El volumen de pacientes de Rocket Doctor aument贸 un 112% interanual en Alberta, atendiendo a m谩s de 36,000 pacientes en 2024, mientras que la adopci贸n por parte de m茅dicos creci贸 un 218%, pasando de 22 a 70 m茅dicos activos.
Los desarrollos clave incluyen asociaciones con la Central California Alliance for Health (plan de atenci贸n gestionada con 450,000 miembros) y Melanoma Canada, adem谩s del despliegue de su Medical Education Suite en la Facultad de Medicina de la Universidad de Minnesota, con un posible ahorro del 40% en costos de ex谩menes. La compa帽铆a fue reconocida como Top Clinical Innovator por la American Telemedicine Association y consigui贸 posiciones en programas prestigiosos como UC Berkeley Health Engine Accelerator y AARP AgeTech Accelerator.
Treatment.com AI (OTC: TREIF)電� Rocket Doctor 鞚胳垬 鞚错泟 欷戩殧頃� 歆勳爠鞚� 氤搓碃頃橂┌ 臧曤牓頃� 靹膘灔 歆�響滌檧 鞝勲灥鞝� 靹标臣毳� 氤挫棳欤缄碃 鞛堨姷雼堧嫟. Rocket Doctor鞚� 鞎岆矂韮� 歆�鞐� 頇橃瀽 靾橂姅 鞝勲厔 雽�牍� 112% 歃濌皜頃橃棳 2024雲勳棎電� 36,000氇� 鞚挫儊鞚� 頇橃瀽毳� 旃橂頄堨溂氅�, 鞚橃偓 毂勴儩毳犾潃 218% 歃濌皜頃橃棳 22氇呾棎靹� 70氇呾潣 頇滊彊 鞚橃偓搿� 電橃柎雮姷雼堧嫟.
欤检殧 氚滌爠 靷暛鞙茧電� 45毵� 氇� 須岇洂鞚� 甏�毽� 鞚橂 瓿勴殟鞚� Central California Alliance for Health 氚� Melanoma Canada鞕�鞚� 韺岉姼雱堨嫮, 氙鸽劋靻岉儉 雽�頃欔祼 鞚橁臣雽�頃欖棎靹滌潣 Medical Education Suite 氚绊彫臧� 韽暔霅橂┌, 鞚措ゼ 韱淀暣 鞁滍棙 牍勳毄鞚� 40%旯岇 鞝堦皭頃� 靾� 鞛堨潉 瓴冹溂搿� 旮半寑霅╇媹雼�. 須岇偓電� American Telemedicine Association鞙茧攵�韯� Top Clinical Innovator搿� 鞚胳爼氚涭晿鞙茧┌ UC Berkeley Health Engine Accelerator鞕� AARP AgeTech Accelerator 霌� 甓岇渼 鞛堧姅 頂勲攴鸽灗鞐愲弰 靹犾爼霅橃棃鞀惦媹雼�.
Treatment.com AI (OTC : TREIF) annonce des progr猫s significatifs suite 脿 l'acquisition de Rocket Doctor, mettant en avant de solides indicateurs de croissance et des r茅alisations strat茅giques. Le volume de patients de Rocket Doctor a augment茅 de 112 % en glissement annuel en Alberta, avec plus de 36 000 patients pris en charge en 2024, tandis que l'adoption par les m茅decins a cr没 de 218 %, passant de 22 脿 70 m茅decins actifs.
Les d茅veloppements cl茅s incluent des partenariats avec la Central California Alliance for Health (un r茅gime de soins g茅r茅s comptant 450 000 membres) et Melanoma Canada, ainsi que le d茅ploiement de leur Medical Education Suite 脿 la facult茅 de m茅decine de l'Universit茅 du Minnesota, ce qui pourrait r茅duire les co没ts des examens de 40 %. L'entreprise a 茅t茅 reconnue comme Top Clinical Innovator par l'American Telemedicine Association et a obtenu des places dans des programmes prestigieux tels que l'UC Berkeley Health Engine Accelerator et l'AARP AgeTech Accelerator.
Treatment.com AI (OTC: TREIF) meldet bedeutende Fortschritte nach der 脺bernahme von Rocket Doctor und zeigt starke Wachstumskennzahlen sowie strategische Erfolge. Das Patientenaufkommen von Rocket Doctor stieg in Alberta um 112 % im Jahresvergleich und versorgte 2024 眉ber 36.000 Patienten, w盲hrend die Anzahl der aktiven 脛rzte von 22 auf 70 um 218 % zunahm.
Zu den wichtigsten Entwicklungen z盲hlen Partnerschaften mit der Central California Alliance for Health (ein Managed-Care-Plan mit 450.000 Mitgliedern) und Melanoma Canada sowie der Einsatz ihrer Medical Education Suite an der medizinischen Fakult盲t der Universit盲t Minnesota, was die Pr眉fungskosten um 40 % senken k枚nnte. Das Unternehmen wurde von der American Telemedicine Association als Top Clinical Innovator ausgezeichnet und erhielt Pl盲tze in renommierten Programmen wie dem UC Berkeley Health Engine Accelerator und dem AARP AgeTech Accelerator.
- Patient volume grew 112% year-over-year in Alberta with 36,779 patients served
- Physician adoption increased 218% from 22 to 70 active physicians
- Medical Education Suite deployment could reduce exam costs by 40% at University of Minnesota
- Secured partnership with Central California Alliance for Health serving 450,000 members
- 35% of Alberta patients are from underserved communities with fewer than 25,000 residents
- Integration costs and challenges following the Rocket Doctor acquisition may impact short-term performance
- Significant expansion and partnerships may require substantial capital investment
- Treatment.com AI completed the acquisition of Rocket Doctor, aligning AI-powered clinical intelligence with a proven virtual care delivery platform.鈥�
- Rocket Doctor patient volume grew
112% in Alberta year-over-year, with over 36,000 patients seen in 2024 and physician adoption growing218% . - 鈥廚ew partnerships launched in California and Canada, including with Central California Alliance for Health, a ~450,000 member managed care plan and Melanoma Canada, a National organization.
- 鈥廙edical Education Suite deployed at University of Minnesota, delivering scalable AI-driven clinical training and potential
40% cost savings. - Rocket Doctor named Top Clinical Innovator by the American Telemedicine Association and invited to speak at Harvard Medical School and AARP鈥檚 AgeTech Accelerator.
鈥廡he quarter began with the finalization of Treatment鈥檚 acquisition of 鈥忊��, marking a pivotal milestone in the company鈥檚 mission to combine a proprietary AI knowledge engine with real-world virtual care delivery. This unified offering creates the potential for smarter, faster, and safer care, powered by the Global Library of Medicine (GLM), AI triage tools, and Rocket Doctor鈥檚 scalable proprietary electronic medical record and digital health platform, all designed by and for practicing physicians.鈥�
鈥廎ollowing the acquisition, Rocket Doctor experienced a
鈥廙eanwhile, Treatment.com AI advanced its commitment to next-generation clinical education with the launch of its new generation of the 鈥忊��. Deployed at the University of Minnesota Medical School, the platform featured new AI-simulated patients to assess 240 third-year students during their OSCE exams, enabling both virtual and live testing at scale. According to estimates from Claudio Violato, Associate Dean of the School of Medicine, the solution has the potential to reduce exam administration costs by approximately
鈥廟ocket Doctor also secured new partnerships in both the U.S. and Canada. In California, the company 鈥忊�� with Central California Alliance for Health, a Medi-Cal managed care plan serving approximately 450,000 members. The program enables patients to access urgent, primary, and specialty care from Rocket Doctor鈥檚 physician network.鈥�
鈥廔n Canada, Rocket Doctor 鈥忊�� to expand access to follow-up care for high-risk skin cancer patients in Ontario, Alberta, and British Columbia, supporting earlier intervention and continuity of care in one of the country鈥檚 most prevalent cancer categories.鈥�
鈥廔n recognition of its innovation and clinical impact, Rocket Doctor was named 鈥忊�� at the NEXUS2025 conference. The award highlights Rocket Doctor鈥檚 physician-led virtual care model and its ability to deliver high-quality care at scale.鈥�
鈥廟ocket Doctor was also selected to participate in several high-profile accelerators and thought leadership programs. The company was welcomed into the UC Berkeley Health Engine Accelerator, a competitive, non-dilutive program for healthtech founders. Dr. William Cherniak, CEO and Founder of Rocket Doctor, was invited to speak at Harvard Medical School by Halle Tecco to share insights with medical and business students on building accessible, AI-supported virtual care platforms. He also joined the 2025 AARP AgeTech Accelerator, where he showcased Rocket Doctor鈥檚 work in supporting aging, Medicaid, and Medicare populations across the U.S.鈥�
鈥廡he company鈥檚 growing profile was further amplified on the national stage. Dr. Hamza and Dr. Cherniak were invited to 鈥忊�� at the Canadian Securities Exchange, followed by a joint appearance on the 鈥忊�� discussing the future of AI and virtual care in North America. Dr. Cherniak also 鈥忊�廼n Kelowna, BC, engaging directly with investors on the evolution of healthcare delivery models.鈥�
鈥廇dding to the quarter鈥檚 momentum, Dr. Cherniak, alongside other leading physicians, co-authored a peer-reviewed research paper titled 鈥忊�忊�溾�忊�忊�濃�忊�� The study offers valuable insight into patient behaviour and the role of digital tools in improving health equity.鈥�
鈥忊�淭he past few months have been transformational for both Rocket Doctor and Treatment.com AI,鈥� said Dr. William Cherniak. 鈥淲e鈥檝e aligned behind a shared vision and are now executing across multiple fronts - from clinical training to specialist care - while helping patients and providers reimagine what modern care can look like.鈥濃��
鈥忊�淲e鈥檙e proud of the momentum achieved so far,鈥� said Dr. Essam Hamza, CEO of Treatment.com AI. 鈥淥ur focus remains on combining physician-led care, proven and tested AI tools and strong partnerships to improve healthcare delivery.鈥濃��
鈥�About Treatment.com AI Inc.
鈥廡reatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment.com AI has built a comprehensive, personalized healthcare AI engine - the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. Treatment.com AI鈥檚 GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities.鈥�
鈥廘earn more at鈥忊�� or contact 鈥忊�� .鈥�
鈥廇bout Rocket Doctor Inc.
鈥�
鈥廟ocket Doctor is a technology-driven digital health platform and marketplace that is breaking down obstacles that limit access to quality, comprehensive and cost-effective healthcare. Our proprietary software equips doctors with the tools to run practices in virtual and hybridized in-person/virtual models of care, enabling them to provide tailored care to patients in rural and Northern communities across Canada and on Medicaid in the United States. Leveraging large language models, AI/ML and wireless medical devices, Rocket Doctor is bridging the healthcare divide, connecting patients to equitable and accessible virtual healthcare services regardless of age, location, or financial status鈥忊��. 鈥�
鈥广颈蝉颈迟鈥忊�� or contact 鈥忊��尘别诲颈补蔼谤辞肠办别迟诲辞肠迟辞谤.颈辞鈥�鈥�.鈥�
鈥�FOR ADDITIONAL INFORMATION, CONTACT:鈥�
鈥�鈥廌r. Essam Hamza, CEO鈥�
鈥庘�廍mail: [email protected]鈥�
鈥庘�廙edia inquiries: [email protected]鈥�
鈥庘�廋all: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955鈥�
鈥廋autionary Statement鈥�
鈥廡his news release contains forward-looking statements that are based on Treatment.com AI鈥檚 expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.鈥�
鈥�The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.鈥�
听
FAQ
What are the key growth metrics for Treatment.com AI (TREIF) following the Rocket Doctor acquisition?
How many patients has Rocket Doctor served in Alberta since Treatment.com AI's acquisition?
What major partnerships did Treatment.com AI (TREIF) secure in 2025?
What cost savings can Treatment.com AI's Medical Education Suite provide?
What major recognition did Treatment.com AI receive in 2025?
